GLP-3 (R)
GLP-3 (R)
A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Considered a next-generation obesity drug. The glucagon component boosts energy expenditure and liver fat metabolism, while GLP-1 and GIP reduce appetite and improve insulin action.
Price range: $ 53 through $ 257
✓ Exceptional weight loss (up to 24%+ in Phase 2 trials)
✓ Rapid fat reduction including visceral fat
✓ Improved metabolic markers (glucose, lipids, liver enzymes)
✓ Increased energy expenditure via glucagon pathway
✓ Promising MASH/fatty liver treatment
7 days
